Profile data is unavailable for this security.
About the company
Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.
- Revenue in HKD (TTM)889.17m
- Net income in HKD263.38m
- Incorporated2018
- Employees484.00
- LocationAlphamab OncologyNo. 175Fangzhou Road, Suzhou Industrial ParkSuzhou 215125ChinaCHN
- Phone+86 51 262850800
- Websitehttps://www.alphamabonc.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics Co Ltd | 362.43m | -216.98m | 4.61bn | 337.00 | -- | 17.79 | -- | 12.71 | -0.9769 | -0.9769 | 1.63 | 1.15 | 0.2903 | 4.05 | 9.14 | 1,069,106.00 | -17.90 | -- | -28.45 | -- | 72.44 | -- | -61.64 | -- | 1.43 | -23.19 | 0.7466 | -- | -- | -- | 33.91 | -- | -- | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 227.81m | -51.64m | 4.80bn | 211.00 | -- | 4.90 | -- | 21.06 | -0.0667 | -0.0667 | 0.2945 | 1.24 | 0.1547 | -- | 7.97 | 886,437.60 | -3.51 | -36.09 | -4.01 | -39.58 | 100.00 | 65.67 | -22.67 | -283.16 | -- | -- | 0.1415 | -- | 145.13 | -- | 56.64 | -- | 29.33 | -- |
| TYK Medicines Inc | 121.05k | -316.86m | 4.85bn | 163.00 | -- | 11.72 | -- | 40,063.00 | -0.8545 | -0.8545 | 0.0003 | 1.09 | 0.0002 | -- | -- | 791.18 | -42.68 | -- | -- | -- | 13.08 | -- | -263,981.30 | -- | -- | -- | 0.3215 | -- | -- | -- | -1.18 | -- | -- | -- |
| Laekna Inc | 0.00 | -271.77m | 5.72bn | 84.00 | -- | 6.48 | -- | -- | -0.7389 | -0.7389 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | -27.79 | -- | -34.25 | -- | -- | -- | -- | -- | -- | -- | 0.1383 | -- | -- | -- | 31.05 | -- | -- | -- |
| Edding Genor Group Holdings Ltd | 253.42m | 22.79m | 6.19bn | 17.00 | 68.82 | 1.31 | 178.11 | 24.41 | 0.0449 | 0.0449 | 0.488 | 2.37 | 0.1724 | -- | 5.21 | 10,559,100.00 | 1.46 | -48.63 | 1.72 | -55.19 | 99.56 | 97.88 | 8.45 | -2,303.07 | -- | -- | 0.0007 | -- | -- | 73.71 | 92.40 | -- | -43.79 | -- |
| MiRXES Holding Co Ltd | -100.00bn | -100.00bn | 7.01bn | 347.00 | -- | 7.87 | -- | -- | -- | -- | -- | 2.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.83 | -- | 0.1682 | -- | -16.14 | -- | -33.37 | -- | -- | -- |
| Lepu Biopharma Co Ltd | 792.43m | -200.47m | 8.25bn | 546.00 | -- | 9.27 | -- | 10.41 | -0.1172 | -0.1172 | 0.4632 | 0.4929 | 0.2917 | 2.35 | 18.33 | 1,591,226.00 | -8.24 | -24.70 | -14.39 | -37.71 | 88.41 | -- | -28.26 | -459.37 | 0.5915 | -5.03 | 0.5632 | -- | 63.21 | -- | -1,761.77 | -- | -29.86 | -- |
| CARsgen Therapeutics Holdings Ltd | 95.08m | -590.45m | 8.59bn | 371.00 | -- | 7.97 | -- | 90.39 | -1.08 | -1.08 | 0.1729 | 1.89 | 0.0465 | 5.13 | 7.63 | 203,167.10 | -28.88 | -76.51 | -32.44 | -89.25 | 50.57 | -- | -621.16 | -12,640.86 | 6.40 | -- | 0.0672 | -- | -- | -- | -6.73 | -- | -28.32 | -- |
| Alphamab Oncology | 889.17m | 263.38m | 8.65bn | 484.00 | 34.03 | 4.08 | 25.13 | 9.73 | 0.2624 | 0.2624 | 0.8935 | 2.19 | 0.3492 | 0.8254 | 23.76 | 2,117,061.00 | 10.35 | -9.96 | 12.30 | -11.75 | 92.27 | -- | 29.62 | -103.28 | 4.75 | -- | 0.1285 | -- | 192.58 | -- | 178.99 | -- | -33.81 | -- |
| Abbisko Cayman Ltd | 700.10m | 169.68m | 8.86bn | 226.00 | 50.60 | 3.53 | 44.76 | 12.66 | 0.2605 | 0.2605 | 1.10 | 3.74 | 0.2634 | -- | 155.74 | 2,491,454.00 | 6.38 | -37.37 | 6.83 | -39.08 | 100.00 | -- | 24.24 | -625.86 | -- | -- | 0.0542 | -- | 2,544.24 | -- | 106.56 | -- | 16.58 | -- |
| GenFleet Therapeutics (Shanghai) Inc | 218.85m | -1.05bn | 11.08bn | 94.00 | -- | -- | -- | 50.63 | -3.04 | -3.04 | 0.6337 | -8.65 | -- | -- | -- | -- | -- | -- | -- | -- | 80.86 | -- | -479.17 | -- | 0.1655 | -23.43 | -- | -- | 42.00 | -- | -33.31 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 203.79m | -249.72m | 12.13bn | 404.00 | -- | -- | -- | 59.51 | -1.54 | -1.54 | 1.26 | -0.4088 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
Data as of Feb 16 2026. Currency figures normalised to Alphamab Oncology's reporting currency: Hong Kong Dollar HKD
2.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 18.87m | 1.94% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 2.02m | 0.21% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 1.93m | 0.20% |
| First Trust Advisors LPas of 06 Feb 2026 | 922.42k | 0.10% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 633.00k | 0.07% |
| Vanguard Fiduciary Trust Co.as of 30 Nov 2025 | 532.91k | 0.06% |
| BlackRock Fund Advisorsas of 05 Feb 2026 | 461.00k | 0.05% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2025 | 380.00k | 0.04% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Jan 2026 | 329.99k | 0.03% |
| Geode Capital Management LLCas of 31 Dec 2025 | 299.00k | 0.03% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
